We are committed to finding a cure for WM.

Cure Magazine covers WM

Cure Magazine’s special issue on Rare Cancers, published on August 1, 2018, includes an article entitled “Waldenstrom Macroglobulinemia: The Discovery and What Lies Ahead”.

The article goes on to describe WM, its rarity, and recent advances in treatment options for… Continue reading

Article: Exploring Use of Ibrutinib/Rituximab Combination for Waldenström Macroglobulinemia

JULY 06, 2018
Kristi Rosa
 
 

A type of non-Hodgkin lymphoma, Waldenström macroglobulinemia is a rare, slow-growing lymphoproliferative disorder that is estimated to affect only 1,000 to 1,500 individuals each year in the… Continue reading

Book Recommendations

 

We are compiling a reading list of books that our members have recommended. Please feel free to send us titles that you have found inspiring and resourceful.

 

HAVE YOU READ……

“Things I wish I’d Known – Cancer Caregivers… Continue reading

FDA Grants Priority Review to Waldenstrom’s Macroglobulinemia Combination Therapy

Source: https://www.raredr.com/news/waldenstroms-macroglobulinemia-combination-therapy-receives-new-drug-designation

Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc announced that the US Food and Drug Administration (FDA) has granted Priority Review for a supplemental New Drug Application (sNDA) for the company’s Waldenström’s macroglobulinemia combination therapy, ibrutinib (IMBRUVICA)… Continue reading

Video: IMBRUVICA (ibrutinib) in Combination With Rituximab for Waldenstrom’s Macroglobulinemia

The following link is to the Cancer Therapy Advisor website featuring the following video

IMBRUVICA (ibrutinib) in Combination With Rituximab for Waldenstrom’s Macroglobulinemia

Meletios Dimopoulos, MD, discusses his findings at the ASCO 2018 meeting in Chicago.

Full link:

https://www.cancertherapyadvisor.com/asco-2018/imbruvica-ibrutinib-combination-rituximab-waldenstrom-macroglobulinemia/article/770910/

Article: Reducing Dose Intensity May Be Associated with Shortened PFS in Waldenstrom Macroglobulinemia

Reducing Dose Intensity May Be Associated with Shortened PFS in Waldenstrom Macroglobulinemia

May 22, 2018

Share this content:

Decreasing the dose intensity (DI) of ibrutinib may reduce progression-free survival (PFS) among patients with Waldenstrom macroglobulinemia (WM)… Continue reading